Sutro Biopharma, Inc. Reports on Annual Meeting of Stockholders

Strategic Insights -

Sutro Biopharma, Inc. has filed a Form 8-K report with the U.S. Securities and Exchange Commission following its 2025 Annual Meeting of Stockholders, where key proposals regarding the election of directors, the appointment of an independent registered public accounting firm, and the approval of executive compensation and a reverse stock split were adopted. The meeting was held on June 6, 2025, and the proposals passed with significant majorities.

Key Takeaways:

  • Three Class I directors, Heidi Hunter, Jon Wigginton, and Michael Dybbs, were elected to serve three-year terms, expiring in 2028.
  • Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
  • The compensation of Sutro Biopharma's named executive officers was approved on a non-binding advisory basis.
  • The amendment of the Company's Restated Certificate of Incorporation to effect a reverse stock split of outstanding common stock at a ratio between 1-for-5 and 1-for-25 was approved.

Statistics:

  • 31,491,009 shares voted for Heidi Hunter and 12,503,128 shares withheld or broker non-votes.
  • 31,496,677 shares voted for Jon Wigginton and 12,503,128 shares withheld or broker non-votes.
  • 31,145,398 shares voted for Michael Dybbs and 12,503,128 shares withheld or broker non-votes.
  • 67,419,553 shares voted for Ernst & Young LLP as the independent registered public accounting firm.
  • 42,988,166 shares voted for the approval of executive compensation on a non-binding advisory basis.
  • 12,355,370 shares voted against executive compensation.
  • 573,051,935 shares voted for the amendment to effect a reverse stock split.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025.